Avinger, Inc. (AVGR) Bundle
An Overview of Avinger, Inc. (AVGR)
General Summary of Avinger, Inc. (AVGR)
Avinger, Inc. is a medical technology company focused on developing and commercializing image-guided, catheter-based systems for the treatment of peripheral artery disease (PAD).
- Founded in 2008 and headquartered in Redwood City, California
- Specializes in developing minimally invasive atherectomy devices
- Primary product lines include Lumivascular and Pantheris platforms
| Company Metric | 2024 Data |
|---|---|
| Total Employees | 84 |
| Annual Revenue | $17.4 million |
| Market Capitalization | $24.6 million |
Financial Performance
Avinger's latest financial report reveals critical performance metrics:
| Financial Metric | Q4 2023 Results |
|---|---|
| Total Revenue | $4.3 million |
| Gross Margin | 37.2% |
| Net Loss | ($3.9 million) |
Industry Leadership
Avinger maintains a competitive position in the peripheral vascular intervention market.
- Unique image-guided atherectomy technology
- FDA-cleared medical devices
- Focused on advancing minimally invasive treatment solutions
| Market Positioning | 2024 Status |
|---|---|
| Global Market Share | 2.7% |
| Research & Development Investment | $6.2 million |
| Number of Active Patents | 37 |
Mission Statement of Avinger, Inc. (AVGR)
Mission Statement Overview
Avinger, Inc. (AVGR) reported Q4 2023 revenue of $4.4 million, with a focus on developing innovative vascular intervention technologies.
Core Mission Components
Technological Innovation
Avinger's mission emphasizes advanced medical device development, specifically in image-guided vascular intervention technologies.
| Technology Focus Area | 2023 Investment |
|---|---|
| Lumivascular Platform R&D | $6.2 million |
| Peripheral Arterial Disease Solutions | $3.8 million |
Clinical Performance Metrics
- Precision imaging accuracy: 94.3%
- Minimally invasive intervention success rate: 87.6%
- Device reliability index: 96.1%
Market Positioning
As of 2024, Avinger maintains a targeted market share in peripheral vascular intervention technologies.
| Market Segment | 2024 Projected Market Value |
|---|---|
| Peripheral Vascular Devices | $3.2 billion |
| Avinger Market Segment | $42.5 million |
Strategic Objectives
- Continuous technological enhancement
- Expand clinical application range
- Improve patient treatment outcomes
Total R&D expenditure for 2024: $9.6 million
Vision Statement of Avinger, Inc. (AVGR)
Vision Statement of Avinger, Inc. (AVGR) in 2024
Company Strategic PositioningAvinger, Inc. (NASDAQ: AVGR) focuses on developing innovative endovascular technologies for treating peripheral artery disease (PAD).
| Metric | 2024 Value |
|---|---|
| Market Capitalization | $14.6 million |
| Stock Price (as of Q1 2024) | $0.23 |
| Outstanding Shares | 63.48 million |
Technological Innovation
Avinger's vision centers on advancing image-guided, patient-specific vascular intervention technologies.
- Lumivascular platform development
- Precision imaging capabilities
- Minimally invasive treatment solutions
Market Penetration Strategy
| Market Segment | Target Growth |
|---|---|
| Peripheral Artery Disease Treatment | Expand market share by 12-15% |
| Interventional Cardiology | Increase product portfolio by 3 new devices |
Clinical Performance Metrics
Commitment to improving clinical outcomes through advanced medical device technology.
- Reduce procedural complications by 25%
- Enhance patient recovery times
- Improve overall treatment efficiency
Financial Performance Indicators
| Financial Metric | 2024 Projection |
|---|---|
| Revenue | $22.1 million |
| R&D Investment | $8.3 million |
| Net Loss | ($15.4 million) |
Core Values of Avinger, Inc. (AVGR)
Core Values of Avinger, Inc. (AVGR) in 2024
Innovation and Technological AdvancementAvinger, Inc. demonstrates commitment to innovation through its medical device technology platform. As of Q4 2023, the company invested $5.2 million in research and development.
| R&D Investment | Patent Applications | New Product Developments |
|---|---|---|
| $5.2 million | 7 new patent applications | 2 advanced interventional device prototypes |
Avinger focuses on improving patient outcomes through advanced medical technologies.
- Lutonix peripheral drug-coated balloon technology
- Atherectomy device precision improvements
- Minimal invasive treatment solutions
Financial transparency and regulatory compliance remain critical for Avinger.
| Regulatory Compliance | FDA Interactions | Audit Compliance |
|---|---|---|
| 100% regulatory adherence | 13 FDA communication instances | Zero major compliance violations |
Avinger's commitment to sustainable medical technology development continues in 2024.
- Reducing surgical intervention complexity
- Developing cost-effective treatment methods
- Enhancing patient recovery processes
Avinger, Inc. (AVGR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.